Peroxisome proliferator-activated receptors: a therapeutic target in COPD?: Fig. 1—
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Extrapulmonary pathology significantly impairs clinical outcome in chronic obstructive pulmonary disease (COPD). The peroxisome proliferator-activated receptors (PPARs) are implicated in the regulation of several hallmarks of systemic COPD pathology, including cachexia, decreased oxidative muscle metabolism, oxidative stress and systemic inflammation. Recently, expression of PPARs and related cofactors was shown to be reduced in peripheral skeletal muscle of patients with moderate-to-severe COPD and muscle weakness. The current authors hypothesise that impaired peroxisome proliferator-activated receptor signalling may underlie some of the muscular disturbances in chronic obstructive pulmonary disease. Proposed mechanisms will be outlined in the present article, as well as the therapeutic potential of peroxisome proliferator-activated receptor modulation in the treatment of skeletal muscle dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 2×
“Like PPAR-a, PPAR-c is involved in attenuation of the inflammatory response by reducing NF-kB DNA binding and repression of NF-kB activation through inhibition of the NF-kB inhibitor protein (IkB) kinase complex activity [ 12 , 15].”
BackgroundIKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice
Cai, D., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B.-C., Lidov, H. G. W., Hasselgren, P.-O., Frontera, W. R., Lee, J., Glass, D. J., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.027 · Cited by 1,367
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update
Fabbri, L. M., & Hurd, S. S. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00063703 · Cited by 1,277 · cited 1×
“Surprisingly, even in the most recent international guidelines for diagnosis of COPD, staging is still only based on severity of airway obstruction [ 1 ].”
BackgroundMitochondrial biogenesis in mammals: the role of endogenous nitric oxide
Nisoli, E., Clementi, E., Paolucci, C., Cozzi, V., Tonello, C., Sciorati, C., Bracale, R., Valerio, A., Francolini, M., Moncada, S., et al. (2003) · Science · doi:10.1126/science.1079368 · Cited by 1,243
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974 · cited 1×
“Furthermore, a sedentary lifestyle, which is often adopted by COPD patients due to disease-specific limitations, can also underlie reduced levels of PPAR and PGC-1a in skeletal muscle, as it has been shown that physical activity level is an important factor regulating these factors [25, 26 ].”
BackgroundTanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Peroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 1×
“Furthermore, glutathione and ascorbic acid levels in the hearts of diabetic rabbits were increased after PPAR-c activation when compared with diabetic nontreated animals [ 64 ].”
ResultPeroxisome proliferator‐activated receptor δ controls muscle development and oxydative capability
Luquet, S., Lopez‐Soriano, J., Holst, D., Fredenrich, A., Melki, J., Rassoulzadegan, M., & Grimaldi, P. A. (2003) · The FASEB Journal · doi:10.1096/fj.03-0269fje · Cited by 509
Cited by
Systemic manifestations and comorbidities of COPD
Barnes, P. J., & Celli, B. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00128008 · Cited by 1,820
Meyer, A., Zoll, J., Charles, A. L., Charloux, A., de Blay, F., Diemunsch, P., Sibilia, J., Piquard, F., & Geny, B. (2013) · Experimental Physiology · doi:10.1113/expphysiol.2012.069468 · Cited by 90
Mitochondrial Dysfunction in Skeletal Muscle Pathologies
Abrigo, J., Simon, F., Cabrera, D., Vilos, C., & Cabello-Verrugio, C. (2019) · Current Protein & Peptide Science · doi:10.2174/1389203720666190402100902 · Cited by 88
Remels, A. H. V., Gosker, H. R., Verhees, K. J. P., Langen, R. C. J., & Schols, A. M. W. J. (2015) · Endocrinology · doi:10.1210/en.2014-1591 · Cited by 82
Self-citationContribution of the Mitochondria to Locomotor Muscle Dysfunction in Patients with COPD
Taivassalo, T., & Hussain, S. N. A. (2016) · Chest · doi:10.1016/j.chest.2015.11.021 · Cited by 59
Metadata
- Authors
- Remels, A. H., Gosker, H. R., Schrauwen, P., Langen, R. C., & Schols, A. M.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2008-02-29
- Volume
- 31
- Issue
- 3
- Pages
- 502-508
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2136517207
- Cited by
- 40
- References
- 19
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peroxisome proliferator-activated receptors: a therapeutic target in COPD?: Fig. 1—. https://app.cochat.ai/papers/10.1183/09031936.00068207
- The paper
- Remels, A. H., Gosker, H. R., Schrauwen, P., Langen, R. C., & Schols, A. M. (2008). Peroxisome proliferator-activated receptors: a therapeutic target in COPD?: Fig. 1—. European Respiratory Journal. https://doi.org/10.1183/09031936.00068207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.